LY3537982 + Pembrolizumab + Placebo + Cisplatin + Carboplatin + Pemetrexed
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Trial Timeline
Dec 21, 2023 → Jan 1, 2031
NCT ID
NCT06119581About LY3537982 + Pembrolizumab + Placebo + Cisplatin + Carboplatin + Pemetrexed
LY3537982 + Pembrolizumab + Placebo + Cisplatin + Carboplatin + Pemetrexed is a phase 3 stage product being developed by Eli Lilly for Carcinoma, Non-Small-Cell Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06119581. Target conditions include Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06119581 | Phase 3 | Recruiting |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung